Tiago Fauth
Stock Analyst at Wells Fargo
(1.36)
# 3,304
Out of 4,711 analysts
128
Total ratings
35.05%
Success rate
-11.29%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tiago Fauth
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $75 → $88 | $44.22 | +99.00% | 7 | Dec 20, 2024 | |
| SVRA Savara | Initiates: Overweight | $8 | $3.23 | +147.68% | 1 | Dec 20, 2024 | |
| MNKD MannKind | Initiates: Overweight | $9 | $6.85 | +31.39% | 1 | Dec 20, 2024 | |
| KROS Keros Therapeutics | Maintains: Overweight | $88 → $111 | $17.03 | +551.79% | 2 | Dec 11, 2024 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $56 → $68 | $46.24 | +47.06% | 1 | Nov 26, 2024 | |
| TECX Tectonic Therapeutic | Maintains: Overweight | $55 → $79 | $47.44 | +66.53% | 2 | Nov 12, 2024 | |
| VRNA Verona Pharma | Maintains: Overweight | $50 → $64 | $42.02 | +52.31% | 2 | Nov 5, 2024 | |
| WVE Wave Life Sciences | Maintains: Overweight | $11 → $22 | $13.51 | +62.84% | 2 | Oct 16, 2024 | |
| IRON Disc Medicine | Initiates: Overweight | $75 | $64.50 | +16.28% | 1 | Aug 22, 2024 | |
| UTHR United Therapeutics | Maintains: Overweight | $350 → $380 | $359.58 | +5.68% | 4 | Aug 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $207 → $233 | $245.44 | -5.07% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $35 → $2 | $2.53 | -20.95% | 2 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $14 | $2.99 | +368.23% | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $77 | $70.44 | +9.31% | 2 | May 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $62 | $2.24 | +2,667.86% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $89 | $136.38 | -34.74% | 16 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $51 | $19.03 | +168.00% | 3 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $120 | $65.66 | +82.76% | 7 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $120 | $3.27 | +3,569.72% | 6 | May 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $4 | $25.86 | -84.53% | 4 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $2.99 | +368.23% | 4 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $4 | $0.40 | +900.00% | 5 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $9.01 | +188.57% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $28 | $2.85 | +882.46% | 7 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $81 | $33.21 | +143.90% | 11 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8 | $0.69 | +1,055.57% | 5 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $1.69 | +728.40% | 2 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $34 | $1.62 | +1,998.77% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $150 | $4.70 | +3,091.49% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $33.29 | -12.89% | 1 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $3.50 | +271.43% | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $13 | $1.31 | +892.37% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2.5 → $2 | $2.24 | -10.71% | 4 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $297 → $340 | $623.82 | -45.50% | 3 | Dec 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $265 → $259 | $263.38 | -1.66% | 1 | Apr 28, 2021 |
Ultragenyx Pharmaceutical
Dec 20, 2024
Maintains: Overweight
Price Target: $75 → $88
Current: $44.22
Upside: +99.00%
Savara
Dec 20, 2024
Initiates: Overweight
Price Target: $8
Current: $3.23
Upside: +147.68%
MannKind
Dec 20, 2024
Initiates: Overweight
Price Target: $9
Current: $6.85
Upside: +31.39%
Keros Therapeutics
Dec 11, 2024
Maintains: Overweight
Price Target: $88 → $111
Current: $17.03
Upside: +551.79%
PTC Therapeutics
Nov 26, 2024
Maintains: Overweight
Price Target: $56 → $68
Current: $46.24
Upside: +47.06%
Tectonic Therapeutic
Nov 12, 2024
Maintains: Overweight
Price Target: $55 → $79
Current: $47.44
Upside: +66.53%
Verona Pharma
Nov 5, 2024
Maintains: Overweight
Price Target: $50 → $64
Current: $42.02
Upside: +52.31%
Wave Life Sciences
Oct 16, 2024
Maintains: Overweight
Price Target: $11 → $22
Current: $13.51
Upside: +62.84%
Disc Medicine
Aug 22, 2024
Initiates: Overweight
Price Target: $75
Current: $64.50
Upside: +16.28%
United Therapeutics
Aug 20, 2024
Maintains: Overweight
Price Target: $350 → $380
Current: $359.58
Upside: +5.68%
Aug 2, 2024
Maintains: Equal-Weight
Price Target: $207 → $233
Current: $245.44
Upside: -5.07%
Jun 18, 2024
Downgrades: Equal-Weight
Price Target: $35 → $2
Current: $2.53
Upside: -20.95%
May 30, 2024
Initiates: Overweight
Price Target: $14
Current: $2.99
Upside: +368.23%
May 29, 2024
Maintains: Overweight
Price Target: $55 → $77
Current: $70.44
Upside: +9.31%
Aug 11, 2023
Maintains: Outperform
Price Target: $63 → $62
Current: $2.24
Upside: +2,667.86%
Jun 14, 2023
Assumes: Neutral
Price Target: $89
Current: $136.38
Upside: -34.74%
Jun 14, 2023
Assumes: Outperform
Price Target: $51
Current: $19.03
Upside: +168.00%
Jun 14, 2023
Assumes: Outperform
Price Target: $120
Current: $65.66
Upside: +82.76%
May 26, 2023
Reiterates: Outperform
Price Target: $120
Current: $3.27
Upside: +3,569.72%
May 23, 2023
Reiterates: Underperform
Price Target: $4
Current: $25.86
Upside: -84.53%
May 16, 2023
Reiterates: Outperform
Price Target: $14
Current: $2.99
Upside: +368.23%
May 16, 2023
Reiterates: Outperform
Price Target: $4
Current: $0.40
Upside: +900.00%
May 11, 2023
Reiterates: Outperform
Price Target: $26
Current: $9.01
Upside: +188.57%
May 5, 2023
Maintains: Outperform
Price Target: $34 → $28
Current: $2.85
Upside: +882.46%
May 5, 2023
Maintains: Neutral
Price Target: $70 → $81
Current: $33.21
Upside: +143.90%
Mar 24, 2023
Reiterates: Neutral
Price Target: $8
Current: $0.69
Upside: +1,055.57%
Mar 23, 2023
Reiterates: Outperform
Price Target: $14
Current: $1.69
Upside: +728.40%
Mar 10, 2023
Maintains: Outperform
Price Target: $38 → $34
Current: $1.62
Upside: +1,998.77%
Mar 10, 2023
Reiterates: Outperform
Price Target: $150
Current: $4.70
Upside: +3,091.49%
Jan 26, 2023
Initiates: Outperform
Price Target: $29
Current: $33.29
Upside: -12.89%
Dec 16, 2022
Initiates: Outperform
Price Target: $13
Current: $3.50
Upside: +271.43%
Nov 18, 2022
Downgrades: Neutral
Price Target: $25 → $13
Current: $1.31
Upside: +892.37%
May 13, 2022
Maintains: Underperform
Price Target: $2.5 → $2
Current: $2.24
Upside: -10.71%
Dec 20, 2021
Maintains: Neutral
Price Target: $297 → $340
Current: $623.82
Upside: -45.50%
Apr 28, 2021
Maintains: Outperform
Price Target: $265 → $259
Current: $263.38
Upside: -1.66%